Would you consider SBRT for fibrolamellar HCC that is inoperable?

What dosage and fractionation would you consider?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

Do the results of recently presented ACCORD trial for EHC and gallbladder cancers have implications for your adjuvant treatment recommendations?

For a patient with metastatic, poorly differentiated esophageal adenocarcinoma with an excellent systemic response to chemotherapy for 1 year, who now presents with isolated local progression and no new distant disease, would you consider treating the primary site with a higher palliative dose for more durable control?

What are your top takeaways from ASCO GI 2026?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
TrialMatch
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.